SL-401 with Azacitidine or Azacitidine/Venetoclax for AML, MDS, or BPDCN
This study is testing SL-401 in combination with azacitidine, or azacitidine and venetoclax, for people with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN). SL-401 works by targeting leukemia cells and potentially slowing the growth of cancer stem cells. The main goal is to find the safest and highest dose of SL-401 when given with these other drugs. To join, you must be at least 18 years old and have one of these conditions with CD123 / IL3RA expression on your cancer cells. This is a Phase 1 study, meaning it focuses on safety and finding the right dose. The study plans to enroll 72 participants.
- Study design
- This is a Phase 1 interventional study, which means it tests the safety and appropriate dose of the treatments. It plans to enroll 72 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The Maximum Tolerated Dose will be measured at 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
At a glance
Conditions
Where it's being run
3 sites across 3 statesStudy leadership
- Andrew Lane, MD, PhD · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Maximum Tolerated Dose2 years
To determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of SL-401 in combination with azacitidine or in combination with azacitidine and venetoclax in this patient population and evaluate the safety of this regimen